Lupeng

Lupeng Pharmaceutical is a clinical-stage biopharmaceutical company based in Guangzhou, China, specializing in the discovery and development of innovative small molecule therapeutics for oncology and hematology. The company's pipeline is centered on targeting key pathways in cancer cell survival, with lead programs including LP-108, a highly selective Bcl-2 inhibitor, and LP-168, a next-generation covalent BTK inhibitor. Lupeng aims to address unmet medical needs in B-cell malignancies and other hematological cancers through both monotherapy and combination strategies. The company leverages its internal R&D capabilities to advance a diverse portfolio of candidates from discovery through clinical proof-of-concept. Backed by prominent investors like Lilly Asia Ventures and Temasek, Lupeng is expanding its clinical footprint globally, including trials in both China and the United States.